chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician concerning a 23 year old female medical assistant with a history of latex allergy and drug hypersensitivity who on 31-JAN-2008 was vaccinated, IM with the 1st dose of GARDASIL (lot# 659653/1448U). There was no concomitant medication. On 31-JAN-2008 a few hours post vaccination she developed a rash all over body, hives, and was itchy. The patient sought unspecified medical attention. At the time of the report she had not recovered from the events. No further information is available. Follow-up received 04/16/2008. The patient also noted her tongue felt itchy, no swelling, and no shortness of breath. 25mg PO Benadryl was given at 1:45pm. The patient was watched for a half hour and the patient stated felling better, less itchy. The patient sought unspecified medical attention. At the time of follow-up, the patient reported recovering on 31-JAN-2008.
Around January 8, My right arm was itching at Injection Site.  A couple of days later I noticed a faint red ring about the size of a silver dollar.  Today on January 15, the site is swollen, and red with fever.  Itching is still occurring.
Narrative: COVID infection following COVID vaccine series 05/26 Janssen, dose #1 09/13 pt cc: cough, fatigue, headache, myalgias, rhinorrhea, dyspnea exposure: friend from chruch 09/15 COVID swab, result: detected 09/15 SARS-COV-2 Variant Sequencing result: pending 09/22 clinically resolved
AFTER 15 MINUTE OBSERVATION, PT WAS UNABLE TO WALK MORE THAN 10-15 FT BEFORE NEEDING TO SIT BACK DOWN AT WHICH TIME SHE SLOWLY SLID OFF THE CJAIR AND ONTO THE FLOOR (GUIDED BY HER FRIEND WHO ACCOMAPANIED HER).  SHE REMAINED LYING ON THE FLOOR UNTIL MEDICAL PERSONNEL ARRIVED. SHE APPREARED TO HAVE PASSED OUT, HAD VERY BRIEF CONVULSIONS/TREMORS BEFORE COMING TO, AT WHICH TIME SHE WAS ABLE TO REPSOND TO QUESTIONS AND ANSWER THEM. HER PULSE RATE SEEMED WITHIN NORMAL WITH SLIGHTLY ELEVATED RESPIRATORY RATE. MEDICAL PERSONNEL ASSISTED HER FROM THE FLOOR TO THE GURNEY. SHE WAS TAKEN TO THE AMBULANCE IN THE PARKING LOT FOR FURTHER EVALUATION. NO UPDATE ON HER STATUS WAS GIVEN TO US.
Mom called 11/28 to report that patient had reaction 11/13/06 after receiving MMR. She had headache, irritability and lethargy. Mom gave her a hameopathic remedy which seemed to help lethargy. Irritability gradually has subsided.
rotator cuff repair infection; This is a literature report for the following literature source Adverse events following mRNA vaccine administration from a busy orthopedic practice: A series of four cases.  Follow up (17Feb2022): This is a literature report for the following literature source entitled Adverse events following mRNA vaccine administration from a busy orthopedic practice: A series of four cases , JSES Reviews, Reports, and Techniques, 2022; [DOI: 10.1016/j.xrrt.2021.12.003]. This is a follow-up report based on the receipt of the publication; the case has been updated to include additional information identified in the publication.  The initial case was missing the following minimum criteria: Unspecified event. Upon receipt of follow-up information on (17Feb2022), this case now contains all required information to be considered valid.  A 58 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "arthroscopic rotator cuff repair", start date: Mar2020 (unspecified if ongoing); "fall" (unspecified if ongoing); "hypercholesterolemia" (ongoing); "hypertension" (ongoing); "left shoulder rotator cuff tear" (unspecified if ongoing), notes: 4.5 years ago; "right shoulder pain", start date: Feb2021 (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1), for Covid-19 Immunization.  The following information was reported: INFECTIVE TENOSYNOVITIS (medically significant), outcome "recovering", described as "rotator cuff repair infection". The patient underwent the following laboratory tests and procedures: c-reactive protein (normal high range 0.9): 2.2; culture: negative, notes: The cultures were held for 21 days, the final gram stain; diagnostic aspiration: unknown results; magnetic resonance imaging: a full-thickness supraspinatus tear was confirmed; demonstrated a large  loculated fluid collection, notes: in the subacromial space with disruption of the rotator cuff repair and lucency  around the previously placed anchors; red blood cell sedimentation rate (0-15): 45; white blood cell count (5.7-10.5): 7.2. Therapeutic measures were taken as a result of infective tenosynovitis; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event, infective tenosynovitis cannot be completely ruled out. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202200301423 Same article/ drug and different patient/event
Information has been received from a nurse concerning a 19 year old female who on unspecified date was vaccinated with dose 1 and dose 2 of GARDASIL (Lot #'s not provided). Subsequently, on an unspecified date the patient was diagnosed with Addison's disease. Additional information has been requested.  07/14/2008 MR received for DOS 5/08-12/2008 with D/C DX: Addison's Disease, postural hypotension and hypoxia. Pt presented to ER with 1 wk hx of episodes of shortness of breath with tachycardia, most recently accompanied by emesis (last 3 days) and sometimes pain. BP did drop and HR&RR up with orthostatics.  With ambulation O2 sat dropped to 85%.   Treated with Cortisone. To f/u as outpt. 9/25/2008 MR received from PCP including various hospital diagnostics. Seen in F/U for above hospital visit./
neck is all sore; Fainted; aching all over; Fall; temperature was 100; This spontaneous case was reported by a consumer and describes the occurrence of SYNCOPE (Fainted) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No medical history reported).   On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021 at 9:10 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Apr-2021, the patient experienced FALL (Fall) and PYREXIA (temperature was 100). On 06-Apr-2021 at 6:00 AM, the patient experienced PAIN (aching all over). On 06-Apr-2021 at 3:30 PM, the patient experienced SYNCOPE (Fainted) (seriousness criterion medically significant). On 07-Apr-2021, the patient experienced NECK PAIN (neck is all sore). At the time of the report, SYNCOPE (Fainted), NECK PAIN (neck is all sore), PAIN (aching all over), FALL (Fall) and PYREXIA (temperature was 100) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Apr-2021, Body temperature: 100 (High) 100.         No concomitant medications were reported.  On 06 Apr2021 at 6, the patient got up because she was aching all over. The patient fainted (medically significant) on the kitchen floor at about 3:30. Her temperature was 100. Her neck was all sore today 07 Apr 2021, so she was not sure if that was from the fall. Patient stated that she took some pain reliever on 06 Apr 2021.  The patient received both scheduled doses of mRNA-1273 prior to the event, therefore action taken with the drug in response to the event is not applicable.  Very limited information regarding these events has been provided at this time.  Further information has been requested.   This case was linked to MOD-2021-069995 (Patient Link).; Sender's Comments: Very limited information regarding these events has been provided at this time.  Further information has been requested.
drowsiness; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (drowsiness) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced SOMNOLENCE (drowsiness). At the time of the report, SOMNOLENCE (drowsiness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided No Treatment information provided
Redness, swelling & pain @ RUE extends from top of shoulder down to just above the elbow. Ultrasound to rule out cellulitis or abcess. Mild subcutaneous edema & discomfort. Tx: cold compress & otc pain relievers. No underlying fluid collection.
New onset complaint of itching. Reported approx. 1 to 2 hours, post initial Hep-B vaccine, with scattered erythematous papules. Was treated with antihistamine. Further vaccine discontinued. Follow-up with primary doctor.
Initial immediate onset of brain fog, decreased cognitive function, significant fatigue. Progressive muscle atrophy, leg pain, and decreased sensation throughout entire body by August 2021, worst in lower extremities. Developed depression/anxiety Aug 2021 (no prior history). Significant unexplained weight loss (20 lbs). Diagnosed with small fiber neuropathy Oct 2021.  Treatments included: hyperbaric oxygen, Vit C and NAD IV drips, acupuncture, red light therapy, ozone sauna Medications: Gabapentin (discontinued), Fluvoxamine (discontinued),  Zoloft - 50mg every other day (current), vitamin supplements  Outcomes: improving weight gain, muscle gain, endurance, decreased fatigue, decreased LE pain as of Feb 2022. Persistent episodes of depression/anxiety, but less severe. Persistent brain fog and decreased sensation.
Pt. reported hives with previous doses of Moderna, as this was not a severe adverse event we proceeded with vaccination with Pfizer. We pre-administered 25mg of Benadryl orally, however pt. still had itching and tingling sensation in limbs a few minutes after receiving the vaccine. Approximately 15 minutes after injection, we orally administered 60mg of prednisolone, which decreased the itching. As itching was still present after about 45 min of observation after prednisolone administration, we gave pt. another oral dose of Benadryl 25mg. Pt. reported resolution of symptoms shortly thereafter, and we discharged pt. from clinic with prescriptions for oral cetirizine 10mg prn and oral prednisone 60mg prn.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021 at 11:40 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 12-Feb-2021 at 11:40 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 36.61.  Concomitant products were not provided.  On 12-Feb-2021, Excursion time was 11 AM, temperature was 35, total doses given for the day was 55, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 09-Feb-2021, vial was moved to clinic on 12-Feb-2021. 3 vials were sent to clinic. Vaccine BUD date was 10-Mar-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Sore arm, within a week it hurt to extend the arm--not in shoulder joint, but upper arm, 2/22/2016, arm still hurts to move but entire upper arm turned red with several splotches.  Also had two large boils on same arm in January 2016.  Antibiotic cured one.
A report was received from a health care professional on 10/30/03, concerning an unspecified number of vaccinees under 4 years of age who inadvertently received Fluvirin on an unspecified date. No adverse effects had occurred at the time of report. There was insufficient information to determine the reporter's causality assessment. Update 1, 12/01/03: Follow up information received from a health care professional indicated that a 7 month old male vaccinee inadvertently received Fluvirin on 10/23/03 and had not experienced any adverse event at the time of the report. No follow up pending, all information received. Cross reference with: PJP200300957, PJP200400013, PJP200400014, PJP200400015, PJP200400016, PJP200400017, PJP200400019, PJP200400020, PJP200400021, PJP200400022, PJP200400023, PJP200400024.
began to feel like shingles is reoccurring;   I previously had shingles and small bumps came  on my back where the old shingles occurred. this started after 7 days began taking lots of vitamins (Bcomplex/Red Algae/Lysine/Multi-vitamin/etc.)
pt recvd vax 12MAY93 & w/in seconds exp dizziness & 1 to 2 mins later devel a sz type of activity lasting approx 1 min;
Varicella s/p vaccine x 2. #1 11.10.04 Merck 0771P. #2 5.29.08 Merck 18996.
Redoning, swelling and soreness in injection area; malaise, body aches, chills tiredness. All but swelling redness and arm soreness resolved in a day and one half.
Wound care,  right leg wound at home.  He has a history of a right AKA and on September 18 he had a debridement of that leg he was discharged from the hospital to ECF and then discharged home.
pt had recent hospitalization (within last month) with respiratory failure and sepsis; pt required intubation with mechanical ventilation; status did not improve much in the hospital; she was discharged to a nursing home; pt admitted to hospital again 10/16/21 with anemia, cardiomegaly, hyperkalemia, and positive for COVID; started on decadron, COVID vitamins; admitted to ICU and started on Levophed; DNR; palliative care consult; pt died in the hospital
Roughly three weeks after receiving vaccines, pt. developed petechiae and more bruising than normal. His pediatrician ordered a CBC and his platelet count was 6L. She said all other blood components were in the normal range. She diagnosed him with acute ITP and referred us to pediatric hematologist, who has also confirmed diagnosis and plans to monitor blood count monthly.
pt admitted to hospital with delerium secondary to hypoxia, COVID 19 encephalitis; given Decadron, O2 supplementation; admitted to hospice as GIP hospice; dc'd to home with hospice where he passed away; death certificate and med records sent per VAERS request
My heart beating really fast. They called Tachnercardia (spelling). Have not got in to the Doctor yet.
Patient complaint of whole body fever, bodyaches, swollen face, and abdominal pain 1 day after receiving Heplisav-B. Patient came to pharmacy on 5/12/23 and shown me his face and it looks much better, but still swelling
This spontaneous report as received from a registered nurse refers to a patient of unknown age. On 12-APR-2013 the patient was vaccinated with expired ZOSTAVAX (lot # 0364AE, expire date 16-MAR-2013, dose/frequency and route were unspecified). No adverse event reported. The outcome was unknown. Additional information has been requested.
Swelling, warmth, erythema and induration involving a large area of the LUE.
Injection site was red; Injection site itchy; Injection site swollen; Pain on the left arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain on the left arm), VACCINATION SITE ERYTHEMA (Injection site was red), VACCINATION SITE PRURITUS (Injection site itchy) and VACCINATION SITE SWELLING (Injection site swollen) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     Previously administered products included for an unreported indication: TETANUS VACCINE.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced PAIN IN EXTREMITY (Pain on the left arm). On 14-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Injection site was red), VACCINATION SITE PRURITUS (Injection site itchy) and VACCINATION SITE SWELLING (Injection site swollen). On 08-Jan-2021, PAIN IN EXTREMITY (Pain on the left arm) had resolved. At the time of the report, VACCINATION SITE ERYTHEMA (Injection site was red), VACCINATION SITE PRURITUS (Injection site itchy) and VACCINATION SITE SWELLING (Injection site swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Headaches and Pulsating on both sides of neck near jugular ~ for approximately 72 hours after vaccine.  Intermitten neck and jaw pain on left side up to today ~ October 15
Information was received on 25-JUL-2017 from a lawyer regarding a case in litigation concerning a female patient of unknown age.  Medical history, concurrent conditions, or concomitant medication was not provided. It was reported that the patient was vaccinated with a dose of ZOSTAVAX (lot number, dosage, and route of administration not provided) on or about 06-APR-2014 at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 22-JUL-2016, the patient was treated by a physician for blistering vesicular outbreaks, which were diagnosed as severe shingles. She was prescribed Acyclovir for management of her painful condition. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages and required extensive medical care and treatment. As a further proximate result the patient has suffered and will continue to suffer significant medical expenses, pain and suffering and other damages. Additional information has been requested.
Patient received cortisone therapy 2 days after receiving 1st dose of vaccine; This spontaneous case was reported by a consumer and describes the occurrence of POTENTIATING DRUG INTERACTION (Patient received cortisone therapy 2 days after receiving 1st dose of vaccine) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced POTENTIATING DRUG INTERACTION (Patient received cortisone therapy 2 days after receiving 1st dose of vaccine). At the time of the report, POTENTIATING DRUG INTERACTION (Patient received cortisone therapy 2 days after receiving 1st dose of vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient received cortisone therapy on 05Mar2021. After receiving therapy, her doctor found out that her efficacy may have decreased. She is not sure whether to repeat the dose and is calling to find out about efficacy.  No treatment was provided. Concomitant medications included an unspecified thyroid medication and an unspecified heart medication.
He developed the classic case of Rubella-mild rash from head to toe, mild fever, malaise, stuffy nose, tender joints, etc.
Pt recv vax on 11/20/98; on same day pt exp urticaria w/ itching; tx=Benadryl
HAVING AN INFECTION AFTER EACH VACCINE; This is a spontaneous report from a contactable Nurse. A 44-years-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on unspecified date as dose number unknown, single for covid-19 immunisation. Took XELJANZ XR 11mg tablet (Lot Number: Unknown, Expiration date: 28Feb2023) via oral for rheumatoid arthritis from 21Oct2020. The patient medical history and concomitant medications were not reported. On unspecified date, the patient experienced having an infection after each vaccine. Patient stated that stopped XELJANZ due to covid vaccine and having an infection after each vaccine, had been on and off of the XELJANZ for 4 weeks total and reports 4 urinary tract infections on XELJANZ. MD is aware. The outcome of event was unknown.
Fver 102 and diffuse arthralgias, sore throat 2 days after immunization; no rash or LAD.
Several weeks after injection experienced gradual onset of leg pain in areas where I had shingles pain many years previous - behind knees, thighs, groin, butt - very intense when bending down, squatting, putting on clothes, getting in or out of car or on and off bus,  sitting or lying down or getting up from sitting or lying down, rolling over in bed even painful. Gradually increased in severity over months since the injection and has not dissipated. I have practiced yoga with no problems for years, now painful to do it at all. Inhibiting my ability to work. I saw the doctor yesterday, 05/05/2022 - blood test taken and in process of considering treatment.
Child returned home from school with fever of 102 degrees. Tylenol did not help. Went to ER. temp was 103.5 degrees. Child was also vomiting. Discharged home early on 02/20/2003. Temp was still 102 at 1:30pm on 02/20/2003. No vomiting at that time.
c/o dizziness, became pale, diaphoretic, nauseated: p=12--no discernable BP 15 mins p/shot administered; givenEpi & BP & pulse returned to nl p/45 mins;